Dwarfism Drug Brings Mixed Emotions for Little People, Parents
This article is for subscribers only.
An experimental drug to treat dwarfism by lengthening children’s bones is meeting skepticism from the leading U.S. group that represents little people, which questions giving kids a medication that might make them less little.
Parents like Chelley Martinka, whose daughter has the condition, achondroplasia, say they have no intention of giving their children injections of BioMarin Pharmaceutical Inc.’s BMN 111. That won’t change even if the drug lives up to the promise of its early trials, said Martinka, who blogs about her daughter’s condition at “A Is for Adelaide.”